KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Imax (IMAX) Cash & Equivalents (2016 - 2026)

Imax's Cash & Equivalents history spans 17 years, with the latest figure at $146.0 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 50.4% to $146.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $146.0 million, a 50.4% increase, with the full-year FY2025 number at $151.2 million, up 50.28% from a year prior.
  • Cash & Equivalents hit $146.0 million in Q1 2026 for Imax, down from $151.2 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for IMAX hit a ceiling of $162.3 million in Q1 2022 and a floor of $76.2 million in Q4 2023.
  • Historically, Cash & Equivalents has averaged $109.5 million across 5 years, with a median of $100.6 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: crashed 54.82% in 2022 and later soared 50.4% in 2026.
  • Tracing IMAX's Cash & Equivalents over 5 years: stood at $97.4 million in 2022, then dropped by 21.77% to $76.2 million in 2023, then soared by 32.01% to $100.6 million in 2024, then skyrocketed by 50.28% to $151.2 million in 2025, then fell by 3.42% to $146.0 million in 2026.
  • Business Quant data shows Cash & Equivalents for IMAX at $146.0 million in Q1 2026, $151.2 million in Q4 2025, and $143.1 million in Q3 2025.